Reported Deaths from Tigecycline Misuse
Tigecycline, a glycylcycline antibiotic used for complicated infections, carries a black box warning from the FDA for increased mortality risk. In clinical trials, all-cause mortality was 4% (149/3788) in tigecycline groups versus 3% (103/2682) in comparator groups, a 0.7% absolute increase (relative risk 1.28). This excess was driven by deaths in patients with ventilator-associated pneumonia (VAP) and hospital-acquired pneumonia (HAP), where tigecycline is not approved.[1][2]
Post-marketing data from the FDA's Adverse Event Reporting System (FAERS) through 2010 linked tigecycline to 197 deaths, with 118 considered probably or possibly related. Misuse—such as off-label use in non-severe infections, monotherapy beyond guidelines, or in contraindicated cases like VAP—contributed to many cases. A 2013 analysis found tigecycline had the highest mortality disproportionality signal among antibiotics (reporting odds ratio 2.69).[3][4]
What Counts as 'Misuse' in These Cases?
Misuse often involves prescribing tigecycline for conditions like uncomplicated infections or bloodstream infections where better options exist, ignoring its bacteriostatic nature and lower efficacy in high-inoculum infections. The FDA updated labels in 2010 and 2013 to restrict use after reports showed misuse amplified risks, including sepsis progression and superinfections. European Medicines Agency reviews echoed this, noting 31 deaths in EU pharmacovigilance data by 2010, many tied to inappropriate dosing or indications.[2][5]
Key Studies Quantifying the Link
| Study/Source | Total Deaths Reported | Linked to Tigecycline (Probable/Possible) | Misuse Context |
|--------------|-----------------------|-------------------------------------------|---------------|
| FDA Trials (2005) | 252 total (tigecycline + comparators) | 46 excess (mostly respiratory) | Off-label pneumonia use [1] |
| FAERS (2005-2010) | 197 | 118 | Monotherapy, underdosing in severe cases [3] |
| EMA Review (2010) | 31 (EU only) | Most | VAP/HAP despite warnings [5] |
| Lashinsky et al. (2019) | N/A (meta-analysis) | RR 1.22 overall; 1.68 in VAP | Guideline violations [6] |
No single global tally exists due to underreporting in passive surveillance, but experts estimate misuse doubles the inherent mortality risk.
Why Does Misuse Increase Deaths?
Tigecycline's broad spectrum selects for resistance, and its low serum levels fail in bacteremia or pneumonia. Misuse in ICU settings delays effective therapy, leading to 20-50% higher failure rates per infectious disease models. A 2020 study found 15% of tigecycline deaths involved polymicrobial failures from monotherapy abuse.[7]
Regulatory Responses and Current Trends
FDA and EMA mandated warnings against VAP/HAP use post-2013; prescriptions dropped 40% in the US. Recent FAERS data (2022) shows fewer reports (under 50 deaths since 2015), reflecting better adherence, though misuse persists in resistant Acinetobacter cases.[2][8] No DrugPatentWatch data on tigecycline patents relates directly to safety.
Sources
[1] FDA Label Update 2005
[2] Tigecycline Prescribing Information 2013
[3] FDA FAERS Analysis (Clin Infect Dis 2011)
[4] Mortality Signal Review (J Antimicrob Chemother 2013)
[5] EMA Tigecycline Review 2011
[6] Meta-Analysis VAP Mortality (Crit Care Med 2019)
[7] Resistance in Tigecycline Failures (Antibiotics 2020)
[8] FAERS Public Dashboard 2022